| Sep 9 |
Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation
|
| Sep 9 |
Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial
|
| Sep 9 |
Update: Summit Therapeutics' Trial Shows Ivonescimab Significantly Improved Progression-Free Survival, Shares Rise
|
| Sep 9 |
Merck Dives After Summit — Up 66% — Sneaks In With Keytruda-Walloping Punch
|
| Sep 9 |
Biggest stock movers today: BIG, PLTR, SMMT, and more
|
| Sep 9 |
Merck stock reacts to Summit cancer drug outdoing Keytruda
|
| Sep 9 |
Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial
|
| Sep 9 |
Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today
|
| Sep 9 |
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
|
| Sep 9 |
Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
|
